Real-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT study
Authors
Nina Turnsek
Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia
Rok Devjak
Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia
Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
Natalija Edelbaher
Department of Pulmonary Diseases, University Medical Centre Maribor, Pohorje, Slovenia
Ilonka Osrajnik
Department of Pulmonary Diseases, University Medical Centre Maribor, Pohorje, Slovenia
Mojca Unk
Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia
Dusanka Vidovic
Department of Pulmonary Diseases, University Medical Centre Maribor, Pohorje, Slovenia
Tina Jeric
AstraZeneca UK Limited, Branch office in Slovenia, Ljubljana, Slovenia
Urska Janzic
Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia
Language: English
Page range: 371 - 379
Submitted on: Jan 31, 2022
Accepted on: Apr 7, 2022
Published on: Aug 14, 2022
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2022 Nina Turnsek, Rok Devjak, Natalija Edelbaher, Ilonka Osrajnik, Mojca Unk, Dusanka Vidovic, Tina Jeric, Urska Janzic, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.